| Clinical data | |
|---|---|
| Other names | LumiLSD; 10-Hydroxy-9,10-dihydro-LSD; 9,10-Dihydro-10-hydroxy-LSD; 10-OH-9,10-DH-LSD; Lumilysergic acid diethylamide; N,N-Diethyl-9,10-dihydro-10-hydroxylysergamide; N,N-Diethyl-10-hydroxy-6-methylergoline-8β-carboxamide |
| ATC code |
|
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C20H27N3O2 |
| Molar mass | 341.455 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Lumi-LSD, also known as 10-hydroxy-9,10-dihydro-LSD or as N,N-diethyl-9,10-dihydro-10-hydroxylysergamide, is a lysergamide and chemical degradation product of the psychedelic drug lysergic acid diethylamide (LSD). LSD is converted into lumi-LSD by exposure to light, specifically ultraviolet light. Lumi-LSD might also be a metabolite of LSD, but this remains unconfirmed.
Lumi-LSD showed 0.01% (i.e., 10,000-fold lower) of the antiserotonergic activity of LSD in the isolated rat uterus in vitro. As such, lumi-LSD was regarded as essentially inactive in this assay. Similarly, lumi-LSD shows abolished physiological and behavioral effects in animals and is said to be inactive in terms of hallucinogenic effects in humans. Likewise, in contrast to LSD, lumi-LSD was found to be inactive in terms of electroencephalogram (EEG) changes in rabbits.
Unlike LSD, lumi-LSD is not fluorescent.
Other lumi-lysergamides are also known.
Lumi-LSD was first described in the scientific literature by at least 1955.